# Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

> **NCT04440280** · PHASE2 · RECRUITING · sponsor: **Massachusetts Eye and Ear Infirmary** · enrollment: 45 (estimated)

## Conditions studied

- Fuchs Endothelial Corneal Dystrophy

## Interventions

- **DRUG:** N-acetyl cysteine (NAC) 10% solution
- **DRUG:** N-acetyl cysteine (NAC) 20% solution
- **DRUG:** Visine Dry Eye Relief eye drops

## Key facts

- **NCT ID:** NCT04440280
- **Lead sponsor:** Massachusetts Eye and Ear Infirmary
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-16
- **Primary completion:** 2026-04-29
- **Final completion:** 2027-04-30
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04440280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04440280, "Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04440280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*